ClinicalTrials.gg
CompletedNCT04530136Updated Feb 16, 2024Results posted

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

A Phase 2 interventional study of Ruconest in Confirmed Coronavirus Disease, sponsored by Pharming Technologies B.V.. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared to SOC alone.

Read the detailed description

Patients fulfilling all eligibility criteria will be randomized in a 2:1 ratio in an open-label controlled design to treatment with rhC1-INH in addition to SOC or SOC only starting on day 0. The first rhC1-INH treatment will be administered on the same day and continued for a total of 4 days.

02

Conditions studied

  • Confirmed Coronavirus Disease
03

In context

Lead sponsor

Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85 years,
  • Admitted to the hospital because of confirmed positive SARS-CoV-2 (COVID-19 infection).
  • Evidence of pulmonary involvement on CT scan or X-Ray of the chest,
  • Symptom onset within the previous 10 days AND at least one additional risk factor for progression to mechanical ventilation: 1) arterial hypertension, 2) >50 years, 3) obesity (>30.0 kg/m2), 4) history of cardiovascular disease, 5) chronic pulmonary disease, 7) chronic renal disease, 6) C-reactive protein of >35mg/L, 7) oxygen saturation at rest in ambient air of \<94%

Exclusion criteria

Exclusion Criteria:

  • to the class of drugs under study (C1 esterase inhibitor);
  • History or suspicion of allergy to rabbits;
  • Women who are of and not using methods of during the entire study period;
  • Pregnant or breastfeeding females or has a positive serum β-human chorionic gonadotropin (hCG) pregnancy test at screening;
  • Chronic liver disease (any score B or C);
  • Currently admitted to an ICU or expected admission within the next 24 hours; and
  • Currently receiving invasive or non-invasive ventilation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Ruconest

    Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.

    Drug: Ruconest

  • Other
    Standard of Care

    SOC

    Drug: Ruconest

Interventions

  • Patients will be randomized to Ruconest or Standard of Care

    Also known as: SOC

06

What researchers measure

Primary outcomes

  1. Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7

    The disease severity on the 7-point WHO Ordinal Scale on Day 7 was the primary objective of this study. This endpoint had been suggested by the WHO for clinical trials in patients with Covid-19. The ordinal scale measures illness severity over time. The higher score, the worst outcome: meaning score 1, no limitation in activities and score 7, death.

    Time frame: Assessed on each day after enrollment (worst status) with the use of the WHO Ordinal Scale and the score on day 7 will be analyzed stratified by its baseline value

Secondary outcomes

  1. Time to Clinical Improvement

    Time from randomization to an improvement of (at least) two (score) points on the seven-category WHO Ordinal Scale or live discharge from hospital whichever came first within 14 days after enrollment

    Time frame: Daily until day 14

  2. Invasive (Mechanical) or Non-invasive Ventilation

    Admission to ICU with invasive or non-invasive ventilation will be assessed.

    Time frame: Daily until day 14.

  3. Number of Days Hospitalized

    Amount of days the patient is hospitalized during participation in the study.

    Time frame: between D0 and D90

07

Results

Posted Feb 16, 2024

Participant flow

Participants were randomized to two parallel groups in a 2:1 ratio to receive either rhC1INH (intervention) in addition to standard of care (SOC) or SOC treatment (control). Randomization was stratified by the study site before inclusion using randomly permuted block sizes of four.

Participant flow — Overall Study
MilestoneRuconestStandard of Care
Started2711
Completed247
Not completed34
Withdrew: Lost to follow-up23
Withdrew: Withdrawal by subject10
Withdrew: Death01

Outcome measures

PrimaryNumber of Participants With Each Score on WHO 7-point Outcome Scale at Day 7

The disease severity on the 7-point WHO Ordinal Scale on Day 7 was the primary objective of this study. This endpoint had been suggested by the WHO for clinical trials in patients with Covid-19. The ordinal scale measures illness severity over time. The higher score, the worst outcome: meaning score 1, no limitation in activities and score 7, death.

Time frame:
Assessed on each day after enrollment (worst status) with the use of the WHO Ordinal Scale and the score on day 7 will be analyzed stratified by its baseline value
Reported as:
Count of participants · Participants
Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7
ParticipantsRuconestStandard of Care
WHO ordinal scale 160
WHO ordinal scale 2208
WHO ordinal scale 300
WHO ordinal scale 410
WHO ordinal scale 501
WHO ordinal scale 602
Statistical analysis
  • Ruconest vs Standard of Care · Wilcoxon rank test · p = 0.0346
SecondaryTime to Clinical Improvement

Time from randomization to an improvement of (at least) two (score) points on the seven-category WHO Ordinal Scale or live discharge from hospital whichever came first within 14 days after enrollment

Time frame:
Daily until day 14
Reported as:
Mean · days
Time to Clinical Improvement
daysRuconestStandard of Care
Time to Clinical Improvement3.32 ± 0.324.91 ± 1.43
Statistical analysis
  • Ruconest vs Standard of Care · WHO Ordinal Scale · p = 0.4441
SecondaryInvasive (Mechanical) or Non-invasive Ventilation

Admission to ICU with invasive or non-invasive ventilation will be assessed.

Time frame:
Daily until day 14.
Reported as:
Count of participants · Participants
Invasive (Mechanical) or Non-invasive Ventilation
ParticipantsRuconestStandard of Care
Invasive (mechanical) ventilation02
Non-invasive ventilation127
Statistical analysis
  • Ruconest vs Standard of Care · WHO Ordinal Scale for Clin Improvement · p = 0.1021
SecondaryNumber of Days Hospitalized

Amount of days the patient is hospitalized during participation in the study.

Time frame:
between D0 and D90
Reported as:
Mean · days
Number of Days Hospitalized
daysRuconestStandard of Care
Number of Days Hospitalized5.38 ± 1.7611.27 ± 16.01
Statistical analysis
  • Ruconest vs Standard of Care · WHO Ordinal Scale · p = 0.1615

Adverse events

Collected over From signing off ICF till 90 days follow-up period Adverse event date were collected.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruconest0/27 (0%)3/27 (11.1%)23/27 (85.2%)
Standard of Care1/11 (9.1%)2/11 (18.2%)11/11 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventRuconestStandard of Care
Blood beta-D-glucan increasedInvestigations0/271/11
EncephalopathyNervous system disorders0/271/11
DyspneaRespiratory, thoracic and mediastinal disorders0/271/11
HypoxiaRespiratory, thoracic and mediastinal disorders0/271/11
Respiratory failure [Death]Respiratory, thoracic and mediastinal disorders0/271/11
HypotensionVascular disorders0/271/11
ShockVascular disorders0/271/11
HyperglycemiaMetabolism and nutrition disorders2/270/11
LeukocytosisBlood and lymphatic system disorders1/270/11
TachycardiaCardiac disorders1/270/11
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRuconestStandard of Care
TransaminitisInvestigations6/270/11
Fibrin D dimer increasedInvestigations5/271/11
DyspnoeaRespiratory, thoracic and mediastinal disorders3/272/11
Blood lactate dehydrogenase incInvestigations4/271/11
LeukocytosisBlood and lymphatic system disorders3/271/11
NauseaGastrointestinal disorders3/270/11
TachycardiaCardiac disorders2/271/11
ConstipationGastrointestinal disorders1/271/11
SepsisInfections and infestations1/271/11
C-reactive protein increasedInvestigations2/271/11

Baseline characteristics

Analyzed (FAS/ITT - Interim analysis/Overrunning analysis) in interim analysis phase: rhC1INH plus SOC \[n=23\]; SOC alone \[n=9\]. A subsequent (post hoc) analysis was conducted to include all 38 patients, overrunning analysis phase: rhC1INH plus SOC \[n=27\]; SOC alone \[n=11\].

Age, Categorical
Age, Categorical(Participants)RuconestStandard of CareTotal
<=18 years000
Between 18 and 65 years23730
>=65 years448
Age, Continuous
Age, Continuous(years)RuconestStandard of CareTotal
Mean55.93 ± 11.8455.18 ± 8.9955.55 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)RuconestStandard of CareTotal
Female13316
Male14822
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RuconestStandard of CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White25833
More than one race000
Unknown or Not Reported123
Body Mass Index
Body Mass Index(kg/m^2)RuconestStandard of CareTotal
Mean34.58 ± 6.0730.54 ± 8.5532.56 ± 7.31
08

Study locations

4 sites
  • Virtua Marlton Hospital
    Marlton, New Jersey 08053, United States
  • Virtua Memorial Hospital
    Mount Holly, New Jersey 08060, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Virtua Voorhees Hospital
    Voorhees, New Jersey 08043, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Sep 2021, 9 months.

Results were first posted in Feb 2024, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Aug 28, 2020
StartActual
Nov 30, 2020
Primary completionActual
Sep 7, 2021
CompletionActual
Dec 1, 2021
Results first posted
Feb 16, 2024
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04530136
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Nov 30, 2020
Primary completion
Sep 7, 2021
Completion
Dec 1, 2021
Results posted
Feb 16, 2024
Last update
Feb 16, 2024

Study contacts

Jonathan Bernstein, MD
principal investigator · University of Cincinnati

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Conestat alfa

Start the discussion